JP2022508942A5 - - Google Patents
Info
- Publication number
- JP2022508942A5 JP2022508942A5 JP2021547043A JP2021547043A JP2022508942A5 JP 2022508942 A5 JP2022508942 A5 JP 2022508942A5 JP 2021547043 A JP2021547043 A JP 2021547043A JP 2021547043 A JP2021547043 A JP 2021547043A JP 2022508942 A5 JP2022508942 A5 JP 2022508942A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- vaccinia virus
- recombinant vaccinia
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749102P | 2018-10-22 | 2018-10-22 | |
| US62/749,102 | 2018-10-22 | ||
| US201962912344P | 2019-10-08 | 2019-10-08 | |
| US62/912,344 | 2019-10-08 | ||
| PCT/US2019/057134 WO2020086423A1 (en) | 2018-10-22 | 2019-10-21 | Mutant vaccinia viruses and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022508942A JP2022508942A (ja) | 2022-01-19 |
| JP2022508942A5 true JP2022508942A5 (https=) | 2022-10-31 |
Family
ID=70331869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547043A Pending JP2022508942A (ja) | 2018-10-22 | 2019-10-21 | 変異ワクシニア・ウイルスおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210388388A1 (https=) |
| EP (1) | EP3870217A4 (https=) |
| JP (1) | JP2022508942A (https=) |
| KR (1) | KR20210108944A (https=) |
| CN (1) | CN113347993A (https=) |
| AU (1) | AU2019367965A1 (https=) |
| CA (1) | CA3117378A1 (https=) |
| IL (1) | IL282509A (https=) |
| MX (1) | MX2021004403A (https=) |
| WO (1) | WO2020086423A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| CN116615442A (zh) * | 2020-09-08 | 2023-08-18 | 优特力克斯有限公司 | 程序性细胞死亡1多肽变体 |
| WO2022147480A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma, Inc. | Oncolytic virus encoding sialidase and multispecific immune cell engager |
| US20240067936A1 (en) * | 2021-02-26 | 2024-02-29 | Sillajen, Inc. | Oncolytic virus and uses thereof |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| CN113322280A (zh) * | 2021-06-18 | 2021-08-31 | 苏州工业园区唯可达生物科技有限公司 | 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体 |
| CN113481241A (zh) * | 2021-06-18 | 2021-10-08 | 苏州工业园区唯可达生物科技有限公司 | 一种敲除h3l基因的重组痘苗病毒载体 |
| CN113322279A (zh) * | 2021-06-18 | 2021-08-31 | 苏州工业园区唯可达生物科技有限公司 | 一种敲除d8l基因的重组痘苗病毒载体 |
| CN113481240A (zh) * | 2021-06-18 | 2021-10-08 | 苏州工业园区唯可达生物科技有限公司 | 一种敲除l1r基因的重组痘苗病毒载体 |
| CN114058645A (zh) * | 2021-06-22 | 2022-02-18 | 苏州工业园区唯可达生物科技有限公司 | 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体 |
| CN114058643A (zh) * | 2021-06-22 | 2022-02-18 | 苏州工业园区唯可达生物科技有限公司 | 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体 |
| CN114058644A (zh) * | 2021-06-22 | 2022-02-18 | 苏州工业园区唯可达生物科技有限公司 | 一种可以逃逸体内存在的既有抗痘苗病毒中和抗体的重组痘苗病毒载体 |
| GB2614309A (en) | 2021-12-24 | 2023-07-05 | Stratosvir Ltd | Improved vaccinia virus vectors |
| CN114369587B (zh) * | 2021-12-25 | 2024-03-15 | 苏州瀚源新酶生物科技有限公司 | 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用 |
| KR20240003051A (ko) * | 2022-06-29 | 2024-01-08 | 신라젠(주) | Cd55 및 cd59를 동시 발현하는 항암 바이러스 |
| CN116179654B (zh) * | 2022-12-30 | 2023-09-15 | 军事科学院军事医学研究院环境医学与作业医学研究所 | 一种检测水中镉离子的滚环扩增检测体系及其应用 |
| CN116990507B (zh) * | 2023-06-29 | 2025-07-08 | 深圳市新产业生物医学工程股份有限公司 | 一种用于猴痘病毒感染的早期筛查的方法 |
| WO2025184411A1 (en) | 2024-02-27 | 2025-09-04 | Calidi Biotherapeutics (Nevada), Inc. | Serum-resistant eev viruses and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US165477A (en) * | 1875-07-13 | Improvement in smelting-furnaces | ||
| CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| JP4344805B2 (ja) * | 2000-07-07 | 2009-10-14 | 独立行政法人科学技術振興機構 | 遺伝子組換えワクシニアウイルスワクチン |
| JP4802401B2 (ja) * | 2000-11-07 | 2011-10-26 | トランスジェン・ソシエテ・アノニム | 標的化感染特異性を有するポックスウイルス |
| US7645456B2 (en) * | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| US7393533B1 (en) * | 2004-11-08 | 2008-07-01 | La Jolla Institute For Allergy And Immunology | H3L envelope protein immunization methods and H3L envelope passive protection methods |
| US7521195B1 (en) * | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| US7807180B2 (en) * | 2007-08-21 | 2010-10-05 | University Of Massachusetts | Poxvirus methods and compositions |
| WO2009048769A2 (en) * | 2007-10-10 | 2009-04-16 | Kirin Pharma Kabushiki Kaisha | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
| IN2012DN02692A (https=) * | 2009-11-05 | 2015-09-04 | Ct Molecular Med & Immunology | |
| FI20115914L (fi) * | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2013112986A1 (en) * | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| CA3029106A1 (en) * | 2016-06-28 | 2018-01-04 | Universitat Ulm | Complement inhibitors and uses thereof |
| IL264893B (en) * | 2016-08-19 | 2022-08-01 | Sementis Ltd | Vaccines for viruses |
-
2019
- 2019-10-21 EP EP19877342.6A patent/EP3870217A4/en not_active Withdrawn
- 2019-10-21 AU AU2019367965A patent/AU2019367965A1/en not_active Abandoned
- 2019-10-21 CA CA3117378A patent/CA3117378A1/en active Pending
- 2019-10-21 CN CN201980084497.0A patent/CN113347993A/zh active Pending
- 2019-10-21 MX MX2021004403A patent/MX2021004403A/es unknown
- 2019-10-21 WO PCT/US2019/057134 patent/WO2020086423A1/en not_active Ceased
- 2019-10-21 JP JP2021547043A patent/JP2022508942A/ja active Pending
- 2019-10-21 US US17/287,497 patent/US20210388388A1/en not_active Abandoned
- 2019-10-21 KR KR1020217015446A patent/KR20210108944A/ko not_active Ceased
-
2021
- 2021-04-21 IL IL282509A patent/IL282509A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508942A5 (https=) | ||
| US12497440B2 (en) | CS1 targeted chimeric antigen receptor-modified T cells | |
| CN108884164B (zh) | 用于免疫疗法的经修饰细胞 | |
| KR102607152B1 (ko) | 키메라 항원 수용체 | |
| KR101956751B1 (ko) | 키메라 항원 수용체 | |
| AU2019234194B2 (en) | CAR-CD30 T cells for treatment of CD30+ tumors | |
| JP2022534680A5 (https=) | ||
| JP2019023184A5 (https=) | ||
| AU2019205273A1 (en) | Multi-domain immunomodulatory proteins and methods of use thereof | |
| CN104592392B (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| CN104592391B (zh) | 一种双特异性抗体EpCAM×CD3的构建及应用 | |
| CN111234033A (zh) | 多链嵌合抗原受体及其用途 | |
| CN114127112A (zh) | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 | |
| US12496338B2 (en) | CAR for treatment of HIV infection | |
| JP2025517479A (ja) | Ｂｃｍａ－ｃｄ１９を標的とする二重特異性キメラ抗原受容体およびその用途 | |
| WO2022032864A1 (zh) | 一种识别Fc片段的嵌合抗原受体及其应用 | |
| CN113045657A (zh) | 一种人源化抗人bcma单克隆抗体及其car-t细胞 | |
| CN115850505A (zh) | 一种靶向cll1的嵌合抗原受体及其应用 | |
| WO2023088359A1 (zh) | 靶向bcma的嵌合抗原受体及其应用 | |
| WO2022089656A1 (zh) | 两个或多个靶点嵌合抗原受体基因工程载体及其应用 | |
| KR20250121163A (ko) | 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도 | |
| CN120712289A (zh) | 抗原结合结构域及其使用方法 | |
| CN118324924A (zh) | 一种包含人源化cll1抗体的嵌合抗原受体及其应用 | |
| CN118324909A (zh) | 一种人源化cll1抗体及其应用 | |
| EP4731753A2 (en) | Gpc3-targeted molecules and uses thereof |